

### REMARKS

Reconsideration of the Examiner's rejection of the present application is requested respectfully in view of the following remarks.

### STATUS OF THE CLAIMS

At the time of the present Office Action, claims 1-42 were pending, with claims 37-42 standing withdrawn from consideration. Claims 1, 2, 29, 31, 32 and 35 are amended. Claims 8-15, 17, 22-28, 33 and 34 are deleted. No claims are added. Therefore, claims 1-7, 16, 18-21, 29-32, 35 and 36 are presented for consideration.

### SUMMARY OF OFFICE ACTION

In the present Office Action, the Examiner has suggested revisions for the claims in view of applicant's election of the specific compound of Example 1e in the response to the Restriction Requirement of March 24, 2006. The Examiner also noted that various substituent groups need to be appropriately defined in accordance therewith.


### DISCUSSION

In response to the Examiner's suggestions, applicant herein is amending the claims in accordance with the election previously made in response to the Restriction Requirement. It is respectfully submitted that the claims as presently amended do not contain any non-elected subject matter and provide a full response to all of the issues raised in the present Office Action.

It is submitted that all of the claims in the present application are now in condition for allowance, and action to that effect is respectfully requested.

The Commissioner is hereby authorized to charge any additional fees or credit any overpayment resulting from this Amendment to Deposit Account 18-1982.

Respectfully submitted,



---

Ronald G. Ort, Reg. No. 26,969  
Attorney for Applicant

sanofi-aventis U.S. LLC.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-2551  
Telefax (908) 231-2626